McKesson (MCK) concluded the recent trading session at $730.80, signifying a +1.82% move from its prior day's close.
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is how McKesson (MCK) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
McKesson's MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson's strategic execution and long-term positioning, underpinned by record full-year revenues of $359 billion and a 20% year-over-year increase in adjusted earnings per share (to $33.05).
The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sector. The company's strategic focus on high-growth segments together with its divestment of slow-growth units makes McKesson an attractive long-term investment despite its high valuation and low yield.
Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses.
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.